Abstract
This introductory chapter delineates first the scope of the cancer problem, providing an overview on the incidence and mortality caused by cancers worldwide. Cancers are caused by many types of exogenous carcinogens, comprising physical, chemical, and biological agents (including viruses, bacteria, and parasites), and by endogenous processes that cause damage to the genome or facilitate the expansion of cell clones with altered genomes. Usually, several factors interact. Cancers display characteristic properties, prominently uncontrolled cell proliferation that is not balanced by cell death, suppression of replicative senescence, disturbed differentiation, genomic instability, as well as various metabolic changes, which are detailed in a special section. The defining properties of cancers—as opposed to benign tumors—are invasion and metastasis. Rational treatment of cancer requires classification by staging, grading, and histology and is increasingly supported by molecular diagnostics. Current cancer treatment relies primarily on surgery, radiotherapy, and chemotherapy. Cytotoxic chemotherapy is more and more supplemented and—in some cases—replaced by molecularly targeted chemotherapies employing small molecule drugs or antibodies. Their development—in particular—is based on insights from molecular cancer research. Immunotherapies have become more efficient and more widely used. New “genetic therapies” employing nucleic acids or therapeutic viruses add to the options for efficient cancer treatment.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
GLOBOCAN by the IARC reports these data on a regular basis.
- 2.
Given the high costs of many novel cancer therapies, minimizing expenses has become another consideration.
- 3.
The IARC regularly publishes monographs on individual (or classes of) carcinogens that can be freely downloaded.
- 4.
‘While enrichment of “osteotropic” radioactive isotopes from elements with properties similar to calcium (like strontium) in bone tissue may cause damage it can be exploited for treatment of bone metastases.
- 5.
What follows is a highly simplified crude model of tissue homeostasis. It neglects among others that stem cells may also undergo symmetric divisions to maintain their overall number and that early precursor cells may reverse to stem cells following damage.
- 6.
Epigenetic changes may similarly serve as a means for adaptation during tumor expansion as well as under therapy.
- 7.
These include lactylation of histones, e.g., which could be highly relevant in hypoxic cancers.
- 8.
e.g., as stage I–IV, where stage I corresponds to T1N0M0 and stage IV to T3/4N1M1.
- 9.
With increasing numbers and varieties of therapeutic options, third line, etc., treatments have become possible.
Further Reading
Amelio I et al (2014) Serine and glycine metabolism in cancer. Trends Biochem Sci 39:191–198
Bergers G, Fendt SM (2021) The metabolism of cancer cells during metastasis. Nat Rev Cancer 21:162–180
Boroughs LK, De Berardinis RJ (2015) Metabolic pathways promoting cancer cell survival and growth. Nat Cell Biol 17:351–359
Boyd N et al (2016) Rare cancers: a sea of opportunity. Lancet Oncol 17:e52–e61
Chabner BA, Roberts TG (2006) Chemotherapy and the war on cancer. Nat Rev Cancer 2005:65–72
Cullin N et al (2021) Microbiome and cancer. Nat Rev Cancer 21:1317–1341
Ferlay J et al (2021) Cancer statistics for the year 2020: an overview. Int J Cancer. https://doi.org/10.1002/ijc.33588
Hanahan D (2022) Hallmarks of Cancer: new dimensions. Cancer Discov 12:31–46
Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674
Hoxhaj G, Manning BD (2020) The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism. Nat Rev Cancer 20:74–88
Kaelin WG, McKnight SL (2013) Influence of metabolism on epigenetics and disease. Cell 153:56–69
Knippel RJ et al (2021) The cancer microbiome: recent highlights and knowledge gaps. Nat Rev Cancer 21:2378–2295
Kroemer G, Pouyssegur J (2008) Tumor cell metabolism: cancer’s Achilles’ heel. Cancer Cell 13:472–482
Liberti MV, Locasale JW (2016) The Warburg effect: how does it benefit cancer cells? Trends Biochem Sci 41:211–218
Martinez-Reyes I, Chandel NS (2021) Cancer metabolism: looking forward. Nat Rev Cancer 21:669–680
Nishikawa H et al (2021) Cancer cachexia: its mechanism and clinical significance. Int J Mol Sci 22:8491
Pavlova NN, Thompson CB (2016) The emerging hallmarks of cancer metabolism. Cell Metabol 23:27–47
Pitot HC (2002) Fundamentals of oncology, 4th edn. Marcel Dekker
Siegel RL et al (2021) Cancer statistics, 2021. CA Cancer J Clin 71:7–33
Strachan T, Read AP (2019) Human molecular genetics, 5th edn. CRC Press
Sullivan LB et al (2016) Altered metabolite levels in cancer: implications for tumour biology and cancer therapy. Nat Rev Cancer 16:680–693
Sung H et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249
Vineis P, Wild CP (2014) Global cancer patterns: causes and prevention. Lancet 383:549–557
Vogelstein B, Kinzler KW (eds) (2002) The genetic basis of human cancer, 2nd edn. McGraw-Hill
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Schulz, W.A. (2023). An Introduction to Human Cancers. In: Molecular Biology of Human Cancers. Springer, Cham. https://doi.org/10.1007/978-3-031-16286-2_1
Download citation
DOI: https://doi.org/10.1007/978-3-031-16286-2_1
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-16285-5
Online ISBN: 978-3-031-16286-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)